JP7361766B2 - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP7361766B2
JP7361766B2 JP2021514019A JP2021514019A JP7361766B2 JP 7361766 B2 JP7361766 B2 JP 7361766B2 JP 2021514019 A JP2021514019 A JP 2021514019A JP 2021514019 A JP2021514019 A JP 2021514019A JP 7361766 B2 JP7361766 B2 JP 7361766B2
Authority
JP
Japan
Prior art keywords
chloro
methyl
indazol
difluorophenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500425A (ja
JP2022500425A5 (https=
Inventor
イウアグウ，クリスティアナ
イー． パーセラ，カイル
エム ピース，ケヴィン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2022500425A publication Critical patent/JP2022500425A/ja
Publication of JP2022500425A5 publication Critical patent/JP2022500425A5/ja
Application granted granted Critical
Publication of JP7361766B2 publication Critical patent/JP7361766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021514019A 2018-09-14 2019-09-12 ヒト免疫不全ウイルス複製の阻害剤 Active JP7361766B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731196P 2018-09-14 2018-09-14
US62/731,196 2018-09-14
US201862733259P 2018-09-19 2018-09-19
US62/733,259 2018-09-19
PCT/IB2019/057710 WO2020053811A1 (en) 2018-09-14 2019-09-12 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022500425A JP2022500425A (ja) 2022-01-04
JP2022500425A5 JP2022500425A5 (https=) 2022-08-09
JP7361766B2 true JP7361766B2 (ja) 2023-10-16

Family

ID=68240777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514019A Active JP7361766B2 (ja) 2018-09-14 2019-09-12 ヒト免疫不全ウイルス複製の阻害剤

Country Status (4)

Country Link
US (1) US20220089598A1 (https=)
EP (1) EP3849982A1 (https=)
JP (1) JP7361766B2 (https=)
WO (1) WO2020053811A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971987T3 (es) * 2018-10-24 2024-06-10 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de inmunodeficiencia humana
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (en) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
WO2024175044A2 (en) * 2023-02-23 2024-08-29 Ascletis Bioscience Co., Ltd. Inhibitors of human immunodeficiency virus replication, method of making and method of using thereof
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
JP2016510038A (ja) 2013-03-01 2016-04-04 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのアミド化合物
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤
JP2021534102A (ja) 2018-08-09 2021-12-09 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7301000B2 (ja) 2017-05-02 2023-06-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7307747B2 (ja) 2018-04-11 2023-07-12 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての４－オキソ－３，４－ジヒドロキナゾリン化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
JP2016510038A (ja) 2013-03-01 2016-04-04 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのアミド化合物
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤
JP7301000B2 (ja) 2017-05-02 2023-06-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7307747B2 (ja) 2018-04-11 2023-07-12 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての４－オキソ－３，４－ジヒドロキナゾリン化合物
JP2021534102A (ja) 2018-08-09 2021-12-09 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤

Also Published As

Publication number Publication date
WO2020053811A9 (en) 2022-03-03
WO2020053811A1 (en) 2020-03-19
JP2022500425A (ja) 2022-01-04
US20220089598A1 (en) 2022-03-24
EP3849982A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
JP7361766B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7433303B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7500555B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
ES2911948T3 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022509919A (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7532354B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
ES2969030T3 (es) Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
JP2022505841A (ja) ヒト免疫不全ウイルス複製の阻害剤
TW202317574A (zh) Ｃｄｋ２抑制劑
JP6739516B2 (ja) 呼吸器合胞体ウイルス阻害剤
ES2974657T3 (es) Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
JP7386230B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
CN115397424A (zh) 人类免疫缺陷病毒复制的抑制剂
KR20220151655A (ko) 인간 면역결핍 바이러스 복제의 억제제
EP4565584A1 (en) 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer
EA043730B1 (ru) Ингибиторы репликации вируса иммунодефицита человека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231003

R150 Certificate of patent or registration of utility model

Ref document number: 7361766

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150